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The Visceral Adiposity Index (VAI) has recently proven to be an indicator of adipose distribution and function that indirectly
expresses cardiometabolic risk. In addition, VAI has been proposed as a useful tool for early detection of a condition of
cardiometabolic risk before it develops into an overt metabolic syndrome. The application of the VAI in particular populations
of patients (women with polycystic ovary syndrome, patients with acromegaly, patients with NAFLD/NASH, patients with HCV
hepatitis, patients with type 2 diabetes, and general population) has produced interesting results, which have led to the hypothesis
that the VAI could be considered a marker of adipose tissue dysfunction. Unfortunately, in some cases, on the same patient
population, there is conflicting evidence. We think that this could be mainly due to a lack of knowledge of the application limits of
the index, on the part of various authors, and to having applied the VAI in non-Caucasian populations. Future prospective studies
could certainly better define the possible usefulness of the VAI as a predictor of cardiometabolic risk.
1. Introduction
The BMI is wrongly considered a satisfactory predictor of
the percentage of body fat, and it is known that it shows
a curvilinear and not a linear association with the body fat
percentage in both men and women [1].
Beyond the criticisms recently leveled [2] towards the
normalization of weight by the square of the height (normal-
ization suggested in the 19th century by Adolphe Quetelet),
many factors affect the relationship between BMI and body
fat percentage, such as gender, race, high muscle mass
(e.g., subjects who practice body building), and changes in
hydration status (in particular subjects having retention of
extracellular fluids may lead to significant mistakes in inter-
pretation about BMI). In older people, significant changes
also occur in both BMI numerator and denominator.
Also, in 2005 in JAMA Katherine Flegal published one of
the first studies [3] to analyze in detail the correlation between
BMI and all causes of mortality on a large series. This study,
based on National Health and Nutrition Examination Survey
(NHANES) data, showed that BMI is not a good predictor
of mortality risk. A subsequent meta-analysis published in
Lancet in 2006 [4], evaluating 40 epidemiological studies
for a mean followup of 3.8 years, confirmed Flegal’s data.
These data led in 2006 to an editorial [5] published in
Lancet, provocatively titled “Should we continue to use
BMI as a cardiovascular risk factor?” which states that “the
BMI may now be withdrawn permanently as a clinical or
epidemiological tool for evaluation of cardiovascular risk in
both primary and secondary prevention.”
This is a condition which deep-down does not appear
desecrating to those who are concerned with prevention of
cardiovascular disease: in fact the BMI does not appear in any
of the versions of the algorithm of Framingham, one of the
strongest tools for defining coronary and cardiovascular risk.
Indeed, in the Framingham study it was assumed that there
could be “metabolically healthy obese subjects.”
An important contribution to evaluation of the influence
of obesity on cardiovascular risk is the Interheart Study [6],
which shows inconvertible evidence that abdominal obesity
makes a higher contribution than BMI to the probability of
these events. The following year, focusing attention on the
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relation between obesity and heart attack risk, Yusuf et al.
published a study [7] defining the results more accurately,
showing that the association between abdominal adiposity
and coronary heart disease risk is highly significant in all
geographical areas in which Interheart Study data were
collected.
These data incontrovertibly seem to support the use-
fulness of the evaluation of waist circumference (WC) in
cardiovascular risk stratification, having been considered
the most valid index of regional distribution of adipose
tissue. Measurement of body circumferences, although it is
a valid method, requires an accurate performance method
in order to provide reproducible information. Several studies
have shown that WC is strongly related to visceral fat and
abdominal adiposity, more than BMI and waist/hip ratio.
The only limitation of WC is inaccurate distinction
between visceral and subcutaneous adipose tissue in the
abdominal region.
2. A New Method for Evaluation of
Adipose Distribution and Function
(Visceral Adiposity Index)
The Visceral Adiposity Index (VAI) is an empirical-
mathematical model, gender-specific, based on simple
anthropometric (BMI and WC) and functional parameters
(triglycerides (TG) and HDL cholesterol (HDL)), and
indicative of fat distribution and function [8]. It is an
empirical-mathematical model that does not originate from
theoretical assumptions, but from observation in a healthy
normal/overweight population of a linear relationship
between BMI and CV, from which a linear equation has been
extrapolated (Figure 1).
At first a model of adipose distribution (MOAD) was
created based on this linear equation (which shows a strong
correlation with visceral fat mass determined by MRI. Sub-
sequently MOAD was corrected for triglyceride and HDL
cholesterol levels, determining the VAI:
Females: VAI = ( WC
36.58 + (1.89 × BMI)
)
× (
TG
0.81
) × (
1.52
HDL
) ,
Males: VAI = ( WC
39.68 + (1.88 × BMI)
)
× (
TG
1.03
) × (
1.31
HDL
) ,
(1)
where WC is expressed in cm, BMI in K/m2, TG in mmol/L,
and HDL in mmol/L.
The VAI has shown a strong positive correlation with
peripheral glucose utilization during euglycemic hyperinsu-
linemic clamp and seems to be independently associated with
cardio- and cerebrovascular events [8]. In the last three years,
it has been reported on more than 30 publications, in which
the capability of the VAI to express a possible “adipose tissue
dysfunction” and the cardiometabolic risk associated to it
have been evaluated.
3. VAI in the General Population as
a Marker of Cardiometabolic Risk
The main aim of our research field on the VAI has been to
identify a simple clinicalmarker of adipose tissue dysfunction
(indirectly reflecting cardiometabolic risk), before it develops
into an overt metabolic syndrome and/or a cardiovascular
complication. Unfortunately, today there are still no long-
term prospective studies that allow us to evaluate the predic-
tive power of the VAI regarding cardiovascular risk.
Our first study on the VAI [8], in a population of 1,498
Caucasian primary care patients, already showed that there
was a strong independent association with both cardiovascu-
lar (odd ratio (95% CI): 2.45 (1.52–3.95)) and cerebrovascular
events (odd ratio (95% CI): 1.63 (1.06–2.50)); in the same
study, a receiver operating characteristic (ROC) analysis
proved greater sensitivity and specificity of VAI, compared
to its individual components (WC, BMI, HDL, and TG)
with regard to cardiovascular and cerebrovascular events.
In another ROC analysis on 1518 Peruvian adults, in which
various measures of adiposity were evaluated, VAI, WC, and
waist-height ratio (WHtR) were the best predictors of the
individual components of the metabolic syndrome [9]. In
particular, the VAI showed good predictive power regarding
the visceral adiposity-related risk of type 2 diabetes [10–
12] and hypertension [13]. Although in some studies the
increase in VAI was significantly associated with a significant
reduction in insulin sensitivity [8, 14, 15], VAI is not to be seen
as an index of insulin sensitivity, but as an indicator of altered
adipose function which is associated with insulin resistance.
Although the VAI was modelled on a Caucasian pop-
ulation, several studies confirm the validity of its use with
other races. For example, in a large case-control study, a high
VAI is associated with elevated risk of CHD in Chinese men
and women [16]. Moreover, in a large cross-sectional study
on 1,764 primary care patients, through an ROC analysis,
appropriate stratified-for-age cut-offs were identified that
were able to identify a supposed adipose tissue dysfunction
[17] (Table 1).These cut-offs have beenmore or less confirmed
in a recent study (data not yet published) in which adipose
tissue dysfunction was directly investigated through a large
panel of proinflammatory adipokines.
Despite this suggestive evidence, there are also conflicting
data like those shown by an Iranian study, which concluded
that using the “complex” VAI, instead of other simple anthro-
pometric measures, may lead to loss of much information
needed for predicting incident CVD [18]. Another Canadian
study also indicated the nonsuperiority of the VAI, compared
to BMI and WC, in predicting the visceral adipose tissue
change in postmenopausal women during a low-calorie diet
[19]. These data suggest the need for further prospective
studies which take into account the greater variability in the
years of the VAI, compared to other simple anthropometric
measures.
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Table 1: Age-stratified cut-off points of VAI for identification of adipose tissue dysfunction (ATD).
ATD absent Mild ATD Moderate ADT Severe ADT
Age < 30 years ≤2.52 2.53–2.58 2.59–2.73 >2.73
≥30 < 42 years ≤2.23 2.24–2.53 2.54–3.12 >3.12
≥42 < 52 years ≤1.92 1.93–2.16 2.17–2.77 >2.77
≥52 < 66 years ≤1.93 1.94–2.32 2.32–3.25 >3.25
≥66 years ≤2 2.01–2.41 2.42–3.17 >3.17
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Figure 1: Linear relationship observed between BMI and WC in 315 primary care patients, with BMI between 20 and 30Kg/m2 and age
43.46 ± 14.30 years (range 19–83), selected because of absence of diabetes mellitus or FPG ≥ 5.6mmol/L, high blood pressure, dyslipidemia,
metabolic syndrome and cardiovascular disease (CVD). A model of adipose distribution (MOAD) was created based on this gender-specific
linear equation. Taken from Amato et al. [8].
4. VAI in NAFLD and NASH
In the hepatological field, the VAI has been investigated in
several studies in patients with NAFLD, with the main objec-
tive of identifying a clinical marker predictive of evolution
towards necroinflammatory injury and fibrosis [20–25]. In
this respect, there are contrasting results between the various
studies, since according to some authors the VAI accurately
predicted progressive liver histology more accurately than
other validated noninvasive scores and identified patients
withNAFLDat increasedCVDrisk [20, 24, 25], while accord-
ing to other authors [21–23] the VAI is not more powerful
than other anthropometric indices in discriminating steatosis
from steatohepatitis. In our opinion, these discrepancies
are attributable to differences between the patients enrolled,
especially concerning the variables included in the VAI. This
especially applies (as explained in the proper use and limits
section) to the mean of triglyceride levels in the various
populations [26]. Moreover, in the hepatological field, an
interesting result was obtained from a study [27] on patients
with chronic hepatitis C due to genotype 1. In these patients
only older age, high VAI, and fibrosis were independently
associated with moderate-severe necroinflammatory activity
by a logistic regression analysis; a higher VAI also has a
direct correlation with viral load. Probably, adipose tissue
dysfunction (indirectly expressed by the VAI) by way of
free fatty acid and proinflammatory cytokine secretion could
directly participate in both liver steatosis and induction of
inflammation. In this complex interplay between the liver
and adipose tissue, HCV could have an important role. It
is possible not only that adipose tissue could provide fatty
substrates and a proinflammatory status, favouring HCV
replication, but also that HCV could interfere with adipocyte
function indirectly by increasing the inflammatory status and
directly by colonizing adipocytes or immune cells infiltrating
adipose tissue [28, 29].
5. VAI in Various Endocrine Diseases
It is now known that carbohydrate, lipid, and protein
metabolism and the whole cardiovascular system respond to
multiple endocrine signals, including those originating from
the adipose endocrine organ. Therefore, there are several
endocrine diseases that expose the patient to a significant
cardiometabolic risk. This risk is unfortunately not easily
identifiable through the classic systems of valuation (risk
charts, Framingham risk score, etc.) based on classical car-
diovascular risk factors. Nor, in this field, can one rely on the
presence of obesity; it is nowknown that endocrinopathymay
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increase cardiovascular risk even in lean subjects. Therefore,
especially in young patients with endocrine disease, who
have not yet developed an overt metabolic syndrome, the
application of the VAI could give useful information.
5.1. VAI in the Polycystic Ovary Syndrome (PCOS). Insulin
resistance and abdominal obesity are common but not uni-
versal features of PCOS, and they are not always associated
with an increased BMI. Indeed, many studies have shown
that both lean and obese women with PCOS have insulin
resistance [30], though recently it has been shown that in
PCOS there is an intrinsic IR that is further worsened
by increasing BMI [31]. It is also known that obesity is
not necessarily an expression of cardiometabolic risk, given
that there exists “metabolically healthy obesity” in which
the particular gynoid distribution of fat does not confer a
cardiometabolic risk [32]. According to these findings, in
womenwith PCOS, it is necessary to identify a simple clinical
index able to distinguish metabolically healthy polycystic
ovary syndrome (MH-PCOS) from metabolically unhealthy
PCOS (MU-PCOS). In first study of ours [33] it was found
that the oligomenorrhoic phenotypes of PCOS (applying the
Rotterdam criteria) were characterized by a high VAI and a
condition of cardiometabolic risk. Recently in young Korean
women with PCOS, the VAI positively correlated with the
visceral fat area (measured with computed tomography) and
visceral-to-subcutaneous fat ratio and negatively correlated
with the insulin-mediated glucose utilization (M value) dur-
ing euglycemic hyperinsulinemic clamp [14]. Another recent
study shows that in women with PCOS the VAI increases
in relation to the severity of anovulation, insulin resistance,
and inflammation [34]. Recently these findings have led
us to verify whether it was possible to distinguish women
with MH-PCOS from women with MU-PCOS through the
use of simple diagnostic tools such as BMI, waist to hip
ratio (WHR), the at-risk category suggested by Androgen
Excess Society (AES) [35], and the VAI. Despite the risk
according to AES, a BMI > 27 kg/m2 and a VAI > 1.675
have similar diagnostic value in detecting adverse metabolic
profile inwomenwith PCOS, a risk that according toAES and
BMI > 27 kg/m2 criteria tends to overestimate the problem;
therefore, given the simplicity of WC and BMI measurement
and TG and HDL assessment, it has been suggested that the
VAI could be an easy and useful tool for the assessment of
MU-PCOS in daily clinical practice and in population studies
[36].
5.2. VAI in Acromegaly. Untreated acromegalic patients have
a decreased fat mass and increased lean body mass due
to the lipolytic effect of GH [37, 38]. In such patients the
subcutaneous adipose tissue is reduced, but the visceral
adipose tissue secretes a number of cytokines that may cause
adipocyte dysfunction and contribute to insulin resistance in
the liver and skeletal muscle and adversely affect pancreatic
𝛽-cell function [39]. This pathophysiological condition can
escape the dichotomous criteria of metabolic syndrome,
especially because of the absence in many cases of an
increased waist circumference. Although the VAI is a gender-
specific index (separately modelled on healthy women and
healthy men), in women with active acromegaly it is strongly
associatedwith insulin resistance, adipose tissue dysfunction,
and cardiometabolic risk, especially in the postmenopausal
age [40]. In another study [41] theVAI also appears to be asso-
ciated with disease activity, inversely with adiponectin levels,
insulin sensitivity, and insulin secretion, and independently
correlated with GH levels. These data suggest that the VAI
could therefore be used as a useful tool for the assessment
of cardiometabolic risk associated with active acromegaly,
especially in postmenopausal acromegalic women.
5.3. VAI in Prolactinoma. Much is known about the effects
of prolactinomas on the reproductive system, but few data
are yet available regarding metabolism and adipose tissue
function. However, in both men and women alterations have
been observed in the distribution of adipose tissue, probably
related to chronic hyperprolactinemia [42, 43]. In two recent
studies it has been shown that in patients with prolactinoma
cabergoline treatment is able to significantly reduce the VAI
and improvemetabolic profile and insulin sensitivity [44, 45].
In clinical practice, in young patients with prolactinoma
without overtmetabolic involvement, theVAI could be useful
both at diagnosis and during the treatment followup, to
prevent the metabolic complications of the disease.
5.4. VAI in Cushing Disease. The application of VAI in overt
Cushing’s syndrome, on the basis of the typical clinical and
phenotypic alterations of the disease, is probably not very
useful. The fact is that almost all patients with overt Cushing
have a pathological increase inwaist circumference, BMI, and
triglycerides and lower HDL cholesterol. In these patients
(who for the reasons indicated above present a high VAI),
the use of the index adds nothing to simple application of the
metabolic syndrome criteria. Furthermore, if on the one hand
the VAI is probably an indicator of adipose dysfunction, on
the other hand it is known that all patients with Cushing have
visceral fat dysfunction. In our opinion, the only application
field of the VAI in Cushing’s syndrome is epidemiological
studies with a high sample size, taking into account the well-
known limits of the index. In a recent study, the VAI was
tested in 140 patients with Cushing’s syndrome [46]; in this
studywomenwithCushing showed a significantly higherVAI
(considering that inmenwith Cushing the VAI was also high,
compared to values observed in the general population),
consequent of the influence of cortisol excess on visceral
adipose dysfunction. The increase in the VAI, specifically
described in women with Cushing, confirms the loss of
gender-related cardiovascular protection of the women when
they develop an increase in visceral adipose tissue, as also
observed in other endocrine diseases, such as acromegaly and
prolactinoma [40, 44]. On the basis of these experiences, even
if we consider unnecessary the use of the VAI in case-control
studies on Cushing patients versus healthy populations, this
index could show its usefulness in prospective studies which
contemplate therapeutic outcomes.
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6. Proper Use and Limits of Visceral
Adiposity Index
The scientific evidence of the last three years on the use
of VAI has allowed us to understand the usefulness of the
index and especially also its limitations. These have been
summarized in a recent letter to the journal NMCD [26].The
main aspect to consider is that the VAI is an indicator of early
cardiometabolic risk in all borderline conditions in which
overt metabolic syndrome is not present. This is explained
by the fact that three of the variables making up the VAI
(WC, TG, and HDL) are dichotomically expressed in the
criteria for metabolic syndrome. Also, of the four variables
that make up the VAI, triglycerides present the problem of
the wide range of values found in the general population,
and waist circumference the problem of the validity of
measurement in subjects with morbid obesity and pendulous
abdomen. For these reasons it has been recommended in an
individual patient or in small sample studies the VAI should
not be applied, above all in the presence of morbid obesity,
pendulous abdomen, severe hypertriglyceridemia, and/or use
of fibrates [26]. In this regard, we observed that, above values
of serum triglycerides> 3.15mmol/L (279mg/dL), the impact
of triglyceridemia on the VAI becomes very crucial: in these
cases triglycerides alone can provide us with much more
information than the VAI regarding the cardiometabolic
risk associated with adipose dysfunction. The same can also
be said about subjects with morbid obesity, in which even
WC has no great diagnostic value. An example of incorrect
application of the VAI is a recent study in a population with
obstructive sleep apnoea, where the authorswanted to test the
association with the severity of sleep apnoea [47]. In actual
fact, in many patients with this problem morbid obesity and
a metabolic syndrome occurred.
Another important aspect that deserves to be investi-
gated concerns changes in the VAI with a low-calorie diet.
Theoretically a healthy weight loss achieved with a mildly
reduced calorie-balanced diet (which does not result in
intense and rapid lipolysis), possibly accompanied by aerobic
physical activity, should result in a reduction in the VAI.
This aspect has not yet been studied. An original recent
study found that Ramadan fasting in healthy adult men
was associated with significant decreases in body weight,
BMI, waist circumference to height ratio (WHtR), and Body
Adiposity Index (BAI), but we found no significant changes
in the VAI [48]. These data indicate that this particular form
of fasting for a period of about a month, even if it determines
weight loss, does not reduce the cardiometabolic risk.
Another important limitation to consider is the applica-
tion of the VAI in non-Caucasian populations and in patients
aged less than 16 years. The fact is that the numerical factors
of the index arise from a mathematical modelling process
on healthy Caucasian men and women, aged between 19
and 83 years. In this regard a study was recently published
which evaluated the VAI in children [49].The authors rightly
conclude that the VAI should be extrapolated with caution in
this age range. We will add more: the VAI “absolutely should
not be applied in this age range,” because the numerical
factors that make up the formula of the VAI are derived by
the linear equation linking the BMI and waist circumference
in a healthy adult population and mean levels of triglycerides
and HDL cholesterol in the same population (Online-Only
Appendix in [8]).
Having made these considerations, we recommend the
application of VAI in the following populations: healthy or
apparently healthy population with BMI < 40 kg/m2, patients
with one or two of the 5 components of the metabolic
syndrome, women with PCOS, and patients with endocrine
disorders (e.g., acromegaly, adult GH deficiency, hypogo-
nadism, hyperprolactinemia, or abnormal thyroid function).
7. Conclusion
An appropriate use of the VAI (which necessarily implies
absolute knowledge of what we have already defined as limits
of application) could help us in various clinical situations
to assess the complex phenomenon of “adipose tissue dys-
function,” especially in the absence of an overt metabolic
syndrome. Unfortunately, today the ability of the VAI to
express adipose tissue function is only to be seen as a
hypothesis; indeed few studies exist that have evaluated the
correlation between it and adipocytokine production [11, 25,
41]. However, in our recent study [50] we evaluated the cor-
relations among various anthropometric indices (BMI, waist
circumference (WC), hip circumference (HC), waist/hip
ratio (WHR), BAI, and Visceral Adiposity Index (VAI))
and several adipocytokines (visfatin, resistin, leptin, soluble
leptin receptors (sOB-R), adiponectin, ghrelin, adipsin, PAI-
1, vascular endothelial growth factor (VEGF), hepatocyte
growth factor (HGF) TNF-𝛼, hs-CRP, IL-6, and IL-18) in
patients with type 2 diabetes. Our data suggest that the VAI,
among the most common indexes of adiposity assessment,
would be an easy tool for clearly mirroring adipose tissue
dysfunction and its associated cardiometabolic risk.
In conclusion, although still lacking prospective studies
that can attribute a prognostic role to the VAI regarding
cardiovascular risk, given the simplicity of WC and BMI
measurement and triglycerides and HDL cholesterol assess-
ment, we suggest that the VAI would be an easy tool for the
evaluation of adipose tissue dysfunction and its associated
cardiometabolic risk in various patient populations, mainly
in the absence of an overt metabolic syndrome.
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